Association between RASSF1A Promoter Hypermethylation and Oncogenic HPV Infection Status in Invasive Cervical Cancer: a Meta-analysis

Jinyun Li, Tao Huang, Cheng Zhang, Danjie Jiang, Qingxiao Hong, Huihui Ji, Meng Ye, Shiwei DuanAsian 2015 · DOI

Abstract

Cervical carcinoma is the main cause of cancer-related mortality in women and is correlated with more than 15 risk cofactors, including infection of cervical cells with high-risk types of HPV (hrHPV). Indeed, both aberrant methylation of the RASSF1A promoter and hrHPV infection are often observed in cervical carcinomas. The purpose of our meta-analysis was to evaluate the role of RASSF1A promoter methylation and hrHPV infection in cervical cancer. Our meta-analysis involved 895 cervical cancer patients and 454 control patients from 15 studies. Our results suggested that RASSF1A promoter hypermethylation increased the risk of cervical cancer (OR=9.77, 95%CI=[3.06, 31.26], P=0.0001, I2=78%). By grouping cases according to cancer subtypes, we found that HPV infection was higher in cervical squamous cell carcinomas (SCCs) than in cervical adenocarcinomas/ adenosquamous cancers (ACs/ASCs) (OR=4.00, 95%CI=[1.41, 11.30], P=0.009, I2=55%). Interestingly, HPV infection tended to occur in cervical cancers with relatively low levels of RASSF1A promoter methylation (OR=0.59, 95%CI=[0.36, 0.99], P=0.05, I2=0%). Our study provides evidence of a possible interaction between HPV infection and RASSF1A promoter methylation in the development of cervical cancers.

Introduction

High-risk Human Papillomavirus (hrHPV) is established as the primary etiological agent for cervical cancer. However, hrHPV infection alone is often insufficient for oncogenesis, as most infections are transient and cleared by the immune system. This suggests that additional genetic or epigenetic alterations—"second hits"—are required to drive the progression to invasive cancer.

One critical epigenetic mechanism is the silencing of tumor suppressor genes (TSGs) through promoter hypermethylation. RASSF1A (Ras association domain family member 1A) is a potent TSG involved in regulating the cell cycle and apoptosis. While various studies have explored the link between RASSF1A methylation and cervical cancer, findings regarding its prevalence and interaction with HPV status have been inconsistent. This meta-analysis synthesizes data from 15 independent studies to clarify these associations.

Methods

The researchers conducted a systematic literature search across PubMed, China National Knowledge Infrastructure (CNKI), and Wanfang databases for studies published through October 2014. Inclusion criteria required studies to provide quantitative data on RASSF1A methylation and/or HPV status in invasive cervical cancer cases compared to healthy or benign controls.

Flowchart of the study selection process for the meta-analysis.

Data from 15 independent studies were pooled, encompassing a total population of 895 cervical cancer patients and 454 control subjects. Statistical analysis was performed using Review Manager 5, employing random-effects or fixed-effects models based on the $I^2$ heterogeneity metric.

Results

RASSF1A Methylation as a Risk Factor

The meta-analysis confirms that RASSF1A promoter hypermethylation is a significant biomarker for invasive cervical cancer. It was detected in approximately 26% of cancer cases but was nearly absent in control tissues. The pooled analysis revealed that RASSF1A hypermethylation is associated with a 9.77-fold increase in cervical cancer risk (95% CI: 3.06–31.26, $P=0.0001$).

Forest plot showing the association between RASSF1A promoter hypermethylation and cervical cancer risk across 15 studies.

Viral and Histological Associations

The study also examined the prevalence of hrHPV across different histological subtypes. hrHPV infection was found to be 4 times more likely in squamous cell carcinomas (SCCs) compared to adenocarcinomas or adenosquamous cancers (ACs/ASCs) (OR=4.00, 95% CI: 1.41–11.30, $P=0.009$).

Discussion: The "Alternative Pathway" Hypothesis

A key insight from this study is the significant inverse relationship between HPV infection and RASSF1A methylation. HPV-positive patients exhibited a lower rate of RASSF1A methylation compared to HPV-negative patients (OR=0.59, 95% CI: 0.36–0.99, $P=0.05$).

This suggests a potential redundancy in oncogenic pathways. Both the HPV E7 oncoprotein and the RASSF1A protein converge on the Rb-dependent cell cycle checkpoint. If the virus has already compromised this checkpoint, the selective pressure for epigenetic silencing of RASSF1A may be reduced. This "competing" pathway model helps explain why RASSF1A methylation is more frequent in ACs/ASCs, which have lower HPV prevalence, while SCCs are more frequently driven by viral infection.

Limitations

Despite the clear findings, several limitations exist. The search was restricted to English and Chinese publications, which may introduce language bias. Additionally, while the overall sample size is robust, some subgroup analyses (e.g., specific HPV genotypes) were limited by the number of available studies. Further prospective research is needed to confirm the molecular crosstalk between viral proteins and epigenetic machinery.

Conclusion

RASSF1A promoter hypermethylation is a powerful risk factor for cervical cancer and may serve as a valuable diagnostic biomarker, particularly in HPV-negative cases. Understanding the interplay between viral infection and epigenetic silencing provides a more nuanced view of cervical cancer development across different histological subtypes.

Summary updated

Abstract

Cervical carcinoma is the main cause of cancer-related mortality in women and is correlated with more than 15 risk cofactors, including infection of cervical cells with high-risk types of HPV (hrHPV). Indeed, both aberrant methylation of the RASSF1A promoter and hrHPV infection are often observed in cervical carcinomas. The purpose of our meta-analysis was to evaluate the role of RASSF1A promoter methylation and hrHPV infection in cervical cancer. Our meta-analysis involved 895 cervical cancer patients and 454 control patients from 15 studies. Our results suggested that RASSF1A promoter hypermethylation increased the risk of cervical cancer (OR=9.77, 95%CI=[3.06, 31.26], P=0.0001, I2=78%). By grouping cases according to cancer subtypes, we found that HPV infection was higher in cervical squamous cell carcinomas (SCCs) than in cervical adenocarcinomas/ adenosquamous cancers (ACs/ASCs) (OR=4.00, 95%CI=[1.41, 11.30], P=0.009, I2=55%). Interestingly, HPV infection tended to occur in cervical cancers with relatively low levels of RASSF1A promoter methylation (OR=0.59, 95%CI=[0.36, 0.99], P=0.05, I2=0%). Our study provides evidence of a possible interaction between HPV infection and RASSF1A promoter methylation in the development of cervical cancers.
BibTeX
@inproceedings{li2015association,
  author = {Jinyun Li and Tao Huang and Cheng Zhang and Danjie Jiang and Qingxiao Hong and Huihui Ji and Meng Ye and Shiwei Duan},
  title = {{Association between RASSF1A Promoter Hypermethylation and Oncogenic HPV Infection Status in Invasive Cervical Cancer: a Meta-analysis}},
  booktitle = {Asian},
  year = {2015},
  doi = {10.7314/apjcp.2015.16.14.5749},
}
Figure